Clinical Trials Browser

Active not recruiting × INDUSTRY × 90 days × Clear all

NCT02257736 2026-03-19

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 3 Active not recruiting

982 enrolled 15 charts

Prostatic Neoplasms

NCT02365597 2026-03-19

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Phase 2 Active not recruiting

239 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT02531516 2026-03-19

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT03491683 2026-03-19

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Phase 1/2 Active not recruiting

Glioblastoma

NCT03875235 2026-03-19

TOPAZ-1

Phase 3 Active not recruiting

810 enrolled 24 charts 1 FDA

Gastrointestinal

Biliary Tract Neoplasms

NCT04083976 2026-03-19

RAGNAR

Phase 2 Active not recruiting

316 enrolled 15 charts

Other solid neoplasm

Advanced Solid Tumor

NCT04246086 2026-03-19

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

Phase 1/2 Active not recruiting

Lymphoma, Follicular

NCT04629729 2026-03-19

FT819 in Subjects With B-cell Malignancies

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, B-Cell

NCT04658862 2026-03-19

SunRISe-2

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT05714202 2026-03-19

SunRISe-3

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT06040099 2026-03-19

EMERALD-Y90

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06052306 2026-03-19

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 1 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT06246643 2026-03-19

A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies

Phase 2 Active not recruiting

Solid Malignant Tumors

NCT00099437 2026-03-18

CONFIRM

Phase 3 Active not recruiting

736 enrolled 14 charts

Breast Neoplasms

NCT02838420 2026-03-18

A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Active not recruiting

187 enrolled 14 charts

Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer

NCT03301220 2026-03-18

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Phase 3 Active not recruiting

390 enrolled 12 charts 1 FDA

Smoldering Multiple Myeloma

NCT03478462 2026-03-18

CLOVER-2

Phase 1 Active not recruiting

CNSGenitourinaryLymphoidSarcoma

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Glioma, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT04140500 2026-03-18

Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors

Phase 1/2 Active not recruiting

DermatologicGastrointestinalThoracic

Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04181788 2026-03-18

Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

Phase 1/2 Active not recruiting

155 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT04189172 2026-03-18

MiDura

Active not recruiting

Arnold-Chiari Malformation, Brain Neoplasms, Hydrocephalus, Meningioma, Spinal Cord Injuries, Vascular Malformations

NCT04379635 2026-03-18

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04635384 2026-03-18

ACROBAT

Active not recruiting

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04699188 2026-03-18

KontRASt-01

Phase 1/2 Active not recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT05083169 2026-03-18

MajesTEC-3

Phase 3 Active not recruiting

587 enrolled 1 FDA

Multiple Myeloma

NCT05217446 2026-03-18

SEAMARK

Phase 2 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05610891 2026-03-18

Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

Phase 1 Active not recruiting

Glioma

NCT05629585 2026-03-18

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

Phase 3 Active not recruiting

Breast Neoplasms

NCT05635708 2026-03-18

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05654623 2026-03-18

VERITAC-2

Phase 3 Active not recruiting

624 enrolled 17 charts

Breast Neoplasms

NCT06012435 2026-03-18

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT06487858 2026-03-18

A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT06590857 2026-03-18

TRACY-1

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT06606847 2026-03-18

LADOGA

Phase 2 Active not recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT04077463 2026-03-17

Chrysalis-2

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04133636 2026-03-17

CARTITUDE-2

Phase 2 Active not recruiting

Multiple Myeloma

NCT04191499 2026-03-17

INAVO120

Phase 2/3 Active not recruiting

325 enrolled 14 charts 1 FDA

Breast Neoplasms

NCT04404283 2026-03-17

ECHELON-3

Phase 3 Active not recruiting

238 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Phase 3 Active not recruiting

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT04512235 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Phase 3 Active not recruiting

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT04958239 2026-03-17

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

Phase 1 Active not recruiting

Neoplasms

NCT05044819 2026-03-17

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

Phase 4 Active not recruiting

Epilepsies, Myoclonic, Liver Cirrhosis, Tuberous Sclerosis, Lennox Gastaut Syndrome

NCT05142696 2026-03-17

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Phase 1/2 Active not recruiting

Extensive Stage Small Cell Lung Cancer

NCT05149755 2026-03-17

Evolut™ EXPAND TAVR II Pivotal Trial

Phase NA Active not recruiting

Constriction, Pathologic, Lymphoma, Follicular

NCT05397496 2026-03-17

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05456867 2026-03-17

NIS durvalumab

Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05552976 2026-03-17

SUCCESSOR-2

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT05662345 2026-03-17

ACT-MBC

Active not recruiting

Breast Neoplasms

NCT05794906 2026-03-17

ARASTEP

Phase 3 Active not recruiting

Biochemically Recurrent Prostate Cancer

NCT05846516 2026-03-17

A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT05916313 2026-03-17

A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3

Phase 1 Active not recruiting

Glioma